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The greatest problem for the correct
evaluation of sensitivity of remedias-
tinoscopy lies in the small sizes of
the series reported in the literature.
Small sample size determines wide
confidence intervals, which reflect
a lack of precision in the inference
of the diagnostic value to the general
population.
Furthermore, discussion about confi-
dence intervals is needed to correct
some confusing statements of Drs Lim
and Dusmet. Because the confidence
level represents the likelihood that
another samplewill provide the same re-
sults (in our case, diagnostic sensitivity),
a confidence level of 95%means that 95
out of 100 times, the sample percentages
will fall within the confidence intervals.
When applied to our study, this means
that sensitivity of remediastinoscopy in
95 out of 100 measurements will have
a value between 42% and 77%. In our
measurement—that is, remediastino-
scopy done by our surgical team and
pathologic examinations done by our
pathologists—sensitivity was exactly
61%. To say that this value ‘‘crosses
50%’’ makes no sense at all. The confi-
dence interval is a way of putting
a probability on what future samples
(or repeats of the earlier sampling proce-
dure with different users) would yield.
In other words, it is a way of saying
how repeatable the results are. It does
not state the definitive value of the result
(sensitivity) in the general population
(patients with non–small cell lung can-
cer after induction therapy).
Throughout the phases of design,
data collection, analysis, and report of
the study we kept in mind all STARD
items and checked the appropriateness
of our statements against the STARD
guidelines. Including ‘‘not biopsied
nodal stations’’ in the formula to calcu-
late the diagnostic accuracy is obvious,
compliant with the STARD guidelines,
and consistent with the methods of pre-
vious literature.3 For example, Drs Lim
and Dusmet cited the article of De Leyn
and colleagues,2 in which sensitivity
was calculated by including a consider-
able number of cases with inadequate
exploration of the subcarinal station
(‘‘no biopsy’’) in which residual metas-
tases were discovered at further thora-
cotomy (‘‘false-negative’’ result of
remediastinoscopy). In the evaluation
of diagnostic yield of remediastino-
scopy, inadequatebiopsyof ametastatic
lymph node station with a false-nega-
tive finding and no biopsy of the station
are two faces of the same coin, the in-
ability of the method to rule in disease,
regardless of what factor leads to the
false-negative result (fibrotic alteration
of nodal tissue after previous mediasti-
noscopy, dense adhesions with ana-
tomic inaccessibility, and so on).
Finally, we remind the readers that
the accuracy value of remediastinoscopy
was as high as 88%. The ability to rule
in residual disease (specificity) was
present in 100% of cases. The ability
to rule out residual disease (sensitivity)
was present in 61%; that is, unnecessary
thoracotomy could be avoided for about
two thirds of patients.
On the basis of these considerations,
we reaffirm our conclusion that reme-
diastinoscopy provides histologic
proof of mediastinal staging with
high diagnostic accuracy.
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To the Editor:
Lim and Dusmet,1 in a letter to the
editors critiquing an article by Marra
and colleagues,2 make 4 statements
about referent values (accuracy, sensi-
tivity, specificity, positive predictive
value, and negative predictive value)3
that require clarification.
Statement 1: ‘‘Specificity (ability to
rule in disease) is not the major focus
for surgeons.’’
Referent value specificity is the
measure of the ability of a test to rule
out disease. It is defined as the number
of patients without the disease who are
identified by the test (true-negative re-
sults) divided by total number of pa-
tients without disease (true-negative
plus false-positive results).
Statement 2: ‘‘What is critical is
sensitivity (the ability to rule out dis-
ease).’’
Referent value sensitivity is a mea-
sure of the ability of a test to rule in
disease. It is defined as the number of
patients with disease who are identi-
fied by the test (true-positive results)
divided by the total number of patients
with the disease (true-positive and
false-negative results).
Statement 3: ‘‘Remediastinoscopy
is associated with 100% specificity.
That in itself is expected . when tu-
mor is seen in a biopsy it is invariably
seen on the reference test.’’
We believe these statements indi-
cate the authors are confusing spe-
cificity with sensitivity. In general,
screening tests have low sensitivity but
high specificity. As work-up continues
and the population is increasingly ‘‘en-
riched’’ with disease, sensitivity in-
creases and specificity decreases.
However, for the surgeon dealing
with this ‘‘enriched’’ population and9
SPIRONOLACTONE
ALLEVIATES LATE CARDIAC
REMODELING AFTER LEFT
VENTRICULAR RESTORATION
To the Editor:
Tsukashita et al1 have performed an
excellent experimental study to show
that spironolactone alleviates remodel-
ing after left ventricular restoration.
When experimental studies are
translated into clinical practice, great
caution should be maintained. Previ-
ous clinical studies on spironolactone
showed a major impact on the pre-
scribing patterns of the doctors. After
the publication of the RALES study,
there was an enormous increase in
the prescription and usage of spirono-
lactone in the late 1990s, leading to
increased hospitalizations mostly due
to hyperkalemia.2 This was attributed
to lack of clinical and laboratory
monitoring, increased doses in pa-
tients with diabetes mellitus, renal
dysfunction, left ventricular ejection
fraction<20%, and elderly patients.2
Approximately 7.5 million of the
elderly patients in the United States
have a glomerular filtration rate <
60 mL/min, and in these patients, spi-
ronolactone causes increased adverse
reactions.3 Microalbuminuria is
a risk factor for heart failure with pre-
vious myocardial ischemia, and spiro-
nolactone has been demonstrated to
reduce microalbuminuria when added
to angiotensin-converting enzyme
inhibitors.4,5
Although spironolactone improves
heart failure symptoms and decreases
microalbuminuria, it should be used
in a selected group of patients. We
need further clinical studies that evalu-
ate the side effect profile to show the
same benefit in humans for alleviating
remodeling following the success of
the experimental study by Tsukashita
et al.1
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Reply to the Editor:
We appreciate the interest that Ram-
araj has shown in our article, and we
are deeply honored by his comments.1
He possesses expertise in a broad area
of medical science, not only in ische-
mic cardiomyopathy, the subject for
our study.
As Ramaraj points out, hyperkale-
mia induced by spironolactone is
a life-threatening side effect clinicians
should look out for. On the other
hand, as cardiovascular surgeons in-
volved in clinical practice, we have
focused on redilatation of the left ven-
tricle in the chronic stage of left
ventricular restoration (LVR) surgery,
searching for any treatment to prevent
it. Although the precise mechanism of
redilatation has not been elucidated,
fibrosis occurred both in border zone
and remote area of plicated infarcted
area in our study, and it was alleviated
by spironolactone. It is well known
that activation of renin-angiotensin-
aldosterone system (RAAS) induces
cardiac fibrosis in autocrine/paracrine
manner. We thought it is possible
that RAAS is one mechanism of
redilatation. Angiotensin-converting
Letters to the Editorwho should not operate if there is
persistent N2 disease after induction
therapy, the referent value, negative
predictive value, is most important. It
is defined as the number of patients
without N2 disease who are identified
by the test (true-negative results) di-
vided by the total number of patients
identified by the test to be without N2
disease (true-negative plus false-nega-
tive results). A high negative predic-
tive value (few false-negative results)
permits the surgeon to confidently
use the results of remediastinoscopy
to plan further surgical intervention.
Statement 4: ‘‘Sensitivity truly
starts at 50% (a test of no sensitivity
or equipoise), not 0%.’’
A referent value has merit through-
out its range. A test with 0% sensitiv-
ity is unable to identify any patient
with disease; one with 100% sensi-
tivity identifies every patient with
disease. Equipoise is equality of distri-
bution, equilibrium, or counterbal-
ance. Although we cannot verify this,
we believe the writers might be con-
fusing the referent value sensitivity
with the area beneath the receiver op-
erator characteristic, expressed as the
C statistic, which is a graph of sensitiv-
ity versus 1 minus specificity. An area
of 0.5 (C ¼ 0.5) might be interpreted
as ‘‘equipoise’’ because this is the ex-
pected relationship between groups
whose testing has produced com-
pletely random results.
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